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Background/Aims: Although magnetic resonance imaging (MRI) is a good visual 
modality for the evaluation of pituitary lesions, it has limited value in the diagno-
sis of mixed nodules and some cystic lesions. We evaluated the usefulness of 18F-
fluorodeoxyglucose positron emission tomography (FDG PET) for patients with 
pituitary lesions.
Methods: 18F-FDG PET and MRI were performed simultaneously in 32 consecu-
tive patients with pituitary lesions. The relationships between FDG uptake pat-
terns in PET and MRI findings were analyzed.
Results: Of 24 patients with piuitary adenomas, 19 (79.2%) showed increased up-
take of 18F-FDG in the pituitary gland on PET scans. All patients with pituitary 
macroadenomas showed increased 18F-FDG uptake on PET scans. Meanwhile, 
only five (50%) of the 10 patients with pituitary microadenomas showed positive 
PET scans. Interestingly, of two patients with no abnormal MRI findings, one 
showed increased 18F-FDG uptake on PET. For positive 18F-FDG uptake, maxi-
mum standardized uptake values (SUVmax) > 2.4 had 94.7% sensitivity and 100% 
specificity. In addition, SUVmax increased in proportion to the size of pituitary 
adenomas. Most cystic lesions did not show 18F-FDG uptake on PET scans.
Consclusions: About 80% of pituitary adenomas showed positivity on PET scans, 
and SUVmax was related to the size of the adenomas. PET may be used as an ancil-
lary tool for detection and differentiation of pituitary lesions.
Keywords: Pituitary; Positron-emission tomography; Magnetic resonance imag-
ing
INTRODUCTION
In 1899, X-ray provided the first visual documentation 
of an enlarged sella turcica in a patient with acromeg-
aly [1]. In the 1970s and 1980s, computed tomography 
(CT) and magnetic resonance imaging (MRI) were 
introduced into clinical practice. These imaging tech-
nologies revolutionized the diagnosis and manage-
ment of patients with pituitary diseases [1]. MRI, with 
improved resolution, has since the 1990s been the first 
choice for diagnosing pituitary lesions [2]. MRI can 
display surrounding structures as well as pituitary 
lesions [3]. Nevertheless, differentiating some cystic 
lesions from mass-related changes, such as cystic 
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changes or hemorrhage, by MRI is sometimes prob-
lematic [4].
Positron emission tomography (PET) with 18F-
fluorodeoxyglucose (18F-FDG) is a valuable method for 
the diagnosis and staging of malignancies as well as 
monitoring their therapeutic effectiveness. PET is also 
helpful for some diagnoses that are difficult to obtain 
with MRI. However, PET has not been frequently used 
for the diagnosis of pituitary tumors. There are lim-
ited data on the diagnostic value of PET for pituitary 
tumors.
In this regard, we experienced one interesting case 
involving Rathke’s cleft cysts (RCC) (case 27). A 59-year-
old woman was referred to the hospital due to symp-
toms of panhypopituitarism and visual disturbances. 
Because brain MRI revealed a focal enhanced mass 
extending over the pituitary gland, optic chiasm, 
and bilateral optic tracts (Fig. 1A), she was first diag-
nosed with optic glioma. Her symptoms spontane-
ously improved, and she was observed for 3 months. A 
subsequent MRI showed improvement in the lesions 
surrounding the optic tract, whereas a cystic lesion in 
the pituitary fossa had expanded. A PET scan was per-
formed, and it showed no uptake of 18F-FDG in the pi-
tuitary fossa (Fig. 1B). This suggested that it was more 
likely to be a cystic lesion such as RCC. She underwent 
trans-sphenoidal surgery for confirmation and was 
finally diagnosed with RCC.
Thus, we investigated the usefulness of 18F-FDG PET 
for the diagnosis and evaluation of various pituitary 
lesions.
METHODS
Patients
From January 2005 to August 2010, we performed PET 
and MRI simultaneously in 46 consecutive patients 
who had been investigated for pituitary lesions accord-
ing to presenting symptoms, signs, laboratory data, 
or other imaging studies. We excluded other brain 
Figure 1. Magnetic resonance imaging (MRI) findings and 18F-fluorodeoxyglucose positron emission tomography (FDG PET) 
imaging in a 58-year-old woman with Rathke’s cleft cyst (case 27). (A) T1-weighted MRI with gadolinium contrast. Coronal (upper 
panel) and axial (lower panel) views demonstrate an enhanced mass (white arrows) covering the pituitary gland and optic 
tracts. (B) Sagittal view of the brain on PET imaging showed no abnormal 18F-FDG uptake in the sella turcica (black arrow).
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lesions, including brain parenchymal tumors other 
than pituitary tumors or metastatic brain tumors. 
A total of 32 patients were diagnosed with pituitary 
lesions. We obtained informed consent from all pa-
tients, and this study was conducted with the approval 
of the Ethics Committee at Severance Hospital, Yonsei 
University College of Medicine.
PET scanning
All patients fasted for more than 6 hours prior to the 
test. Sixty minutes after intravenous injection of 7 to 
9 mCi of 18F-FDG, images were obtained using a GE 
ADVANCE PET scanner (GE, Milwaukee, WI, USA). 
Emission scanning continued for 15 minutes (4.25 
mm axial spatial resolution, 4.8 mm transaxial spatial 
resolution). Transmission scans were performed for 8 
minutes using triple Ge-68 rod sources to correct for 
attenuation. Gathered data were reconstructed in a 128 
× 128 × 35 matrix with a pixel size of 1.95 × 1.95 × 4.25 
mm by means of a filtered back-projection algorithm 
employing a transaxial 8.5-mm Hanning filter and 8.5-
mm axial ramp filter. Two experienced nuclear medi-
cine doctors evaluated the 18F-FDG PET images on a 
high-resolution computer screen. The standardized 
uptake value (SUV) was calculated as the concentra-
tion of 18F-FDG uptake divided by injected dose/body 
weight. To avoid a partial volume effect, the maximum 
SUV (SUVmax) was measured within the region of inter-
est.
MRI
MRI was performed at 1.5 T (Intera Achieva, Philips 
Medical Systems, Best, Netherlands). T1- and T2-
weighted spin-echo images were obtained in the coro-
nal and sagittal planes at 3 mm sections. T1-weighted 
images were then obtained after intravenous admin-
istration of 0.1 mmol/kg of gadolinium gadolinium 
diethylenetriamine pentaacetic acid.
Statistics
All data are shown as means ± standard deviations. 
Fisher’s exact test and the Mann-Whitney test were 
applied for comparisons of pituitary lesion character-
istics. The Kruskal-Wallis test was used to compare 
the differences in SUVmax of pituitary cysts, microad-
enomas, and macroadenomas. The statistics program 
used for the analysis was the SPSS package for Win-
dows version 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
In this study, a total of 32 patients who showed pitu-
itary lesions were included. Females (n = 22) comprised 
a larger proportion than males (n = 10), and the mean 
age of the patients was 51.6 years (range, 17 to 80). 
Twenty-four patients had pituitary adenomas, and 
eight had cystic lesions. Of the 24 pituitary adenomas, 
10 were classif ied as functioning tumors and 14 as 
nonfunctioning tumors. There were five patients with 
growth hormone-secreting adenomas, two with pro-
lactinomas, two with Cushing’s disease, and one with 
a thyroid-stimulating-hormone-secreting adenoma. 
Among the eight patients with cystic lesions, seven 
had RCCs, and one had an archnoid cyst (Table 1).
As shown in Table 2, of the 24 patients with pituitary 
adenomas, 19 (79.2%) showed increased uptake of 18F-
FDG on PET scans with a hypermetabolic focus in 
the pituitary gland. On the other hand, uptake of 18F-
FDG on PET was not observed in most cases of cysts 
(n = 8). One exceptional case of cystic lesions showed 
suspicious 18F-FDG uptake in the pituitary gland on 
PET, but the uptake was very low. The total number of 
pituitary macroadenomas (mean size, 18.6 ± 7.0 mm) 
was 14, and all (100%) showed positive 18F-FDG uptake 
on PET scans (Table 2, Fig. 2). The total number of 
pituitary microadenomas was 10, of which five (50.0%) 
showed positive 18F-FDG uptake on PET scans. Posi-
tive uptake of 18F-FDG was shown in eight of 10 (80.0%) 
functioning adenomas and 11 of 14 (78.6%) nonfunc-
tioning adenomas (Table 2).
The SUVmax of 
18F-FDG on PET scans ranged from 
1.9 to 20.5. The mean SUVmax of macroadenomas was 
significantly higher than that of microadenomas or 
cystic lesions (6.6 ± 5.1, 2.6 ± 0.5, and 2.3 ± 0.4; p < 0.05, 
respectively) (Fig. 3). There was a correlation between 
the size and SUVmax of tumors (r = 0.559, p < 0.01). A > 
8.5-mm-maximal diameter of pituitary lesions had 
78.9% sensitivity and 72.7% specificity for positive 18F-
FDG uptake on PET scans. A SUVmax of > 2.4 had 94.7% 
sensitivity and 100% specificity for positive 18F-FDG 
uptake. Although it was not significant, the mean SU-
Vmax of nonfunctioning pituitary adenomas tended to 
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Table 1. Characteristics of patients with pituitary lesions
Case Sex Age, yr Diagnosis
Size of pituitary 
lesion, mm
18F-FDG 
uptake
SUVmax
1 F 35 GH-secreting pituitary adenomaa 29 Positive   5.56
2 F 57 GH-secreting pituitary adenomaa 17 Positive    3.03
3 M 37 GH-secreting pituitary adenomaa 7 Negative   2.29
4 F 59 GH-secreting pituitary adenomaa 10 Positive   2.56
5 F 64 GH-secreting pituitary adenoma 7 Positive   3.47
6 F 23 Prolactinomaa 13 Positive   2.83
7 F 50 Prolactinoma 7 Positive   2.93
8 M 58 Cushing’s diseasea 15 Positive   4.01
9 F 17 Cushing’s diseasea NA Negative   2.16
10 F 80 TSH-secreting pituitary adenomaa 27 Positive 6.1
11 F 38 Nonfunctioning pituitary adenoma 17 Positive  13.14
12 F 80 Nonfunctioning pituitary adenoma 13 Positive   8.16
13 F 49 Nonfunctioning pituitary adenoma 5 Positive    2.42
14 F 66 Nonfunctioning pituitary adenoma 9 Positive         3 
15 F 23 Nonfunctioning pituitary adenoma 10 Positive    1.96
16 M 31 Nonfunctioning pituitary adenoma 6 Negative    2.05
17 M 58 Nonfunctioning pituitary adenoma 5 Negative   2.17
18 M 72 Nonfunctioning pituitary adenoma 30 Positive 20.52
19 M 67 Nonfunctioning pituitary adenoma 26 Positive    3.47
20 F 78 Nonfunctioning pituitary adenoma 22 Positive   7.74
21 F 84 Nonfunctioning pituitary adenoma 12 Positive   7.34
22 F 27 Nonfunctioning pituitary adenomaa 20 Positive  7.2
23 M 39 Nonfunctioning pituitary adenoma 5 Negative    2.06
24 F 68 Nonfunctioning pituitary adenoma NA Positive   3.53
25 F 32 Rathke’s cleft cyst 8 Negative   2.38
26 F 31 Rathke’s cleft cyst 6 Positive    3.44
27 F 58 Rathke’s cleft cyst 19 Negative   2.15
28 F 58 Rathke’s cleft cyst 5 Negative   2.23
29 F 24 Rathke’s cleft cyst 7 Negative   2.17
30 M 67 Rathke’s cleft cyst 5 Negative   2.39
31 M 57 Rathke’s cleft cyst 12 Negative    2.02
32 M 66 Arachnoid cyst 22 Negative    1.95
FDG, fluorodeoxyglucose; SUVmax, maximum standard uptake values; NA, not available.
aDiagnosis confirmed by surgical pathology.
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Table 2. 
18
F-FDG uptake positivity on positron emission tomography according to the characteristics of pituitary lesions
Characteristics of pituitary lesions Total no. of cases
% of positive  
18F-FDG uptake 
p valuea 
Component of pituitary lesions 0.002
Adenoma 24  19 (79.2)
Cystic lesion 8   1 (12.5)
Size of pituitary adenomas 0.060
Macroadenoma 14 14 (100)
Microadenoma 10    5 (50.0)
Function of pituitary adenomas NS
Functioning adenoma 10    8 (80.0)
Nonfunctioning adenoma 14  11 (78.6)
FDG, fluorodeoxyglucose; NS, not significant.
aFisher’s exact test for positron emission tomography positivity.
a
25.0
20.0
15.0
10.0
5.0
0.0
SU
Vm
ax
Cyst Microadenoma Macroadenoma
a
Figure 2. Magnetic resonance imaging findings of nonfunctioning pituitary adenoma (case 11). (A) An approximately 17-mm 
pituitary macroadenoma (black arrow). (B) Round increased uptake (white arrow) in the pituitary fossa (maximum standard 
uptake values, 13.1). 
Figure 3. Distribution of maximum standard uptake values 
(SUVmax) of pituitary lesions (Kruskal-Wallis test). 
ap < 0.05.
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be higher than that of functioning adenomas (mean 
SUVmax, 7.1 ± 5.5 vs. 3.8 ± 1.3).
Table 3 shows the PET scan and MRI findings in 24 
patients with pituitary adenomas. Of these, 22 (91.6%) 
showed positive findings on MRI. Of the two who did 
not show any abnormal findings on MRI, one (case 24) 
showed positive 18F-FDG uptake on PET. The remain-
ing patient (case 9) showed negative FDG uptake on 
PET. Although this 17-year-old female patient present-
ed with prominent symptoms of hypercortisolism, 
neither MRI nor PET showed any abnormal findings. 
She was diagnosed with Cushing’s disease based on 
inferior petrosal sinus sampling and underwent trans-
sphenoidal surgery.
DISCUSSION
MRI is an important method with which to inves-
tigate the anatomical structure of pituitary lesions. 
Nevertheless, differential diagnosis is occasionally dif-
ficult for cystic lesions such as cystic or hemorrhagic 
pituitary adenomas, primary parasellar lesions with 
presentation in the sellar region, and sometimes RCC 
[5,6]. Interestingly, in case 27, MRI did not allow for a 
differential diagnosis between RCC and optic glioma; 
in case 24, an invisible lesion on MRI was positive on 
the FDG PET scan. In addition, MRI generally pro-
vides little information about the biochemical and 
functional characteristics of pituitary tumors.
PET emerged as a functional imaging modality in 
the 1970s for the first time and has since become an 
important diagnostic technique for many diseases. 
PET measures the local concentration of tracers, ob-
tains biochemical information such as glucose uptake, 
and converts them into images. The molecule most 
commonly used as a radiotracer is 18F-FDG; however, 
other diverse tracer molecules have been developed 
and used in various fields. In tumors or metabolically 
active cells, glycolysis is enhanced, and thus the 18F-
FDG uptake rate increases competitively [7,8]. Because 
the size of the normal pituitary gland is small and its 
metabolic rate is low, it does not show 18F-FDG uptake 
on PET scans [9,10]. On the other hand, pituitary ad-
enoma and craniopharyngioma, the cells of which are 
more metabolically active than normal cells, induce 
increased 18F-FDG uptake on PET scans. The 18F-FDG 
uptake rate in pituitary adenoma is 30% higher than 
that in the whole brain [11].
Recently, several cases of pituitary adenomas were 
detected incidentally by 18F-FDG PET [12], as in our 
case 24. One study reported an incidence of pituitary 
incidentaloma by 18F-FDG PET imaging combined 
with CT (PET-CT) of 0.073% (30 of 40,967 patients) 
[13]. This rate is markedly lower than that of inciden-
talomas by MRI or CT (3.7% to 20%) [14,15]. Several 
factors may contribute to this difference. First, whole-
body PET has a lower spatial resolution than MRI for 
pituitary lesions. Second, not all pituitary tumors are 
FDG-avid. Third, there is still no consensus regard-
ing pituitary uptake. 18F-FDG PET as a modality for 
diagnosis of pituitary lesions has been investigated. 
Most of these studies involved specified groups, such 
as patients with Cushing’s disease, acromegaly, or 
other functioning and/or nonfunctioning adenomas. 
In our study, we investigated the usefulness of PET 
as an initial diagnostic imaging study in various 
pituitary lesions. Most cystic lesions did not show 
18F-FDG uptake. Only one patient with RCC (case 26) 
showing heterogeneity on MRI had suspicious uptake 
of 18F-FDG with a low SUVmax on PET. Earlier studies 
demonstrated the usefulness of 18F-FDG in patients 
with pituitary adenomas. De Souza et al. [9] reported 
that five of 12 patients with positive PET scans showed 
negative or questionable lesions on MRI and that 
there were no false-positive cases among all 20 control 
subjects. In this study, the PET positivity rate in mi-
croadenoma was comparable with that of MRI (60% 
Table 3. Comparison of positron emission tomography 
(PET) scans with magnetic resonance imaging (MRI) of the 
pituitary gland in 24 patients with pituitary adenomas
PET
Total
Positive Negative
MRI
Positive   18 (81.8)a 4 (18.2) 22 (100)
Negative 1 (50) 1 (50)b   2 (100)
Total  19 (79.2)  5 (20.8) 24 (100)
Values are presented as number (%).
aPositive predictive value of PET. 
bNegative predictive value of PET.
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vs. 65%, respectively). PET-CT, rather than PET alone, 
is now used frequently. One study investigated the 
diagnostic value of fused 18F-FDG PET-CT in patients 
with Cushing’s disease [16]. They concluded that PET-
CT may be an important diagnostic tool for diagnosis 
of Cushing’s disease because PET-CT might identify 
some Cushing’s-positive patients that had a negative 
MRI [16]. In our study, the overall adenoma positiv-
ity on PET was 79.2%. All patients with pituitary 
macroadenomas showed positive PET scans (100%), 
whereas positive PET scans were shown only in 50% of 
microadenomas. SUVmax may facilitate more accurate 
diagnosis, especially in patients with pituitary micro-
adenomas. Our data showed that a SUVmax of > 2.4 had 
94.7% sensitivity and 100% specificity for positive 18F-
FDG uptake. However, SUVmax may vary depending on 
many factors, such as the size of the mass, standard-
ized measurement times, plasma glucose levels, recov-
ery coefficients, and partial volume effects. Thus, fur-
ther studies of diagnosis using SUVmax with a greater 
numbers of subjects should be conducted.
Mean SUVmax values were higher in macroadenomas 
than in microadenomas or cystic lesions (Fig. 3). They 
also tended to be higher in nonfunctioning adenomas 
than in functioning adenomas, although there was no 
difference in the sizes of these adenoma types (13.8 ± 8.4 
mm vs. 14.6 ± 8.3 mm, respectively). Similarly, in pre-
vious studies it was reported that the 18F-FDG uptake 
levels of nonfunctional pituitary adenomas were high-
er than those of functional pituitary adenomas [11,17]. 
The cause of the higher 18F-FDG uptake by nonfunc-
tional pituitary adenomas has not been elucidated. A 
possible explanation is that in nonfunctional pituitary 
adenomas, energy metabolism rates are higher due to 
incomplete hormone synthesis by the tumor [11]. Sec-
ond, in nonfunctional pituitary adenomas, inhibition 
by the final product is inefficient; thus 18F-FDG uptake 
may be retained [11]. Finally, because 50% of nonfunc-
tional pituitary adenomas show oncocytic changes, 
higher 18F-FDG uptake may have occurred. In onco-
cytomas, which overexpress mitochondria, overrepre-
sentation of the hexokinase enzyme leads to increased 
18F-FDG uptake [17].
18F-FDG PET may facilitate differentiation of re-
curred tumors, residual tumors, inf lammatory reac-
tions after surgery, and fibrosis [9,18]. After surgery, 
when the diagnosis of residual or recurred cancer 
with MRI is unclear due to inflammation or fibrosis, 
PET may assist their differentiation [11]. 18F-FDG PET 
also enables prediction of the treatment response 
and growth potentiality of pituitary adenomas. Bro-
mocriptine decreased the 18F-FDG uptake rates of pro-
lactinomas by up to 20%, and octreotide decreased the 
18F-FDG uptake rates in thyroid stimulating hormone- 
and growth hormone-producing adenomas by up to 
53% [11]. Radiation therapy reportedly leads to a 20% 
to 30% decreased 18F-FDG uptake [11,18]. Therefore, 
the treatment outcome can be assessed by comparing 
the PET findings before and after treatment. Because 
estimation of the functional treatment response, espe-
cially in nonfunctioning pituitary adenomas, is prob-
lematic, changes in 18F-FDG uptake may in such cases 
assist determination of treatment responses.
In conclusion, 18F-FDG PET may represent an ancil-
lary tool for detection and differentiation of pituitary 
lesions in certain circumstances. Further PET stud-
ies to determine the appropriate SUVmax threshold, or 
conjugation of alternative tracer molecules, may facili-
tate more accurate diagnosis of pituitary lesions. In 
addition, studies of the change in FDG uptake rates on 
PET induced by various treatment methods for each 
pituitary disease will be informative.
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KEY MESSAGE
1. In this study, about 80% of pituitary adenoma 
showed positivity on  positron emission tomog-
raphy (PET) scan and maxi mum standardized 
uptake value (SUVmax) was related to the size of 
adenomas.
2. PET could be useful method for detecting and 
differentiating various pituitary lesions.
3. Further PET studies determining the right 
threshold of SUVmax or conjugating various trac-
er molecules will be helpful.
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